Phase II Data from FIT Biotech`s HIV Immunotherapy Show Reduction in Viral Load and Increase in CD4 Cell Count

VIENNA–(Business Wire)–
FIT Biotech, a privately held biotechnology company developing novel,
proprietary immunotherapies for HIV/AIDS and other viral diseases, announced
results today from a Phase II clinical trial. The company`s immunomodulator
FIT-06 showed unprecedented long-term reductions in viral load (approximately
0.5 log) and statistically significant CD4 cell count increases in HIV-infected,
previously untreated patients. The effect lasted longer than two years in the
absence of any anti-retroviral therapy.

The study, carried out in South Africa, represents the first time that an
immune-based HIV intervention has reduced viremia in previously untreated
patients. The results offer hope for an eventual alternative to antiretroviral
therapy (ART) for those millions of HIV-infected patients in the developing
world who have no access to ART. “This is the first demonstration that an
immune-based therapy can interfere with HIV replication in infected people who
have not yet started ART,” said Professor of Medicine Giuseppe Pantaleo of the
University of Lausanne, Switzerland, an investigator on the study. “By analyzing
these patients` immune responses in detail, we will gain invaluable information
to guide us in further improving the vaccine.”

“These results are very exciting as an early indicator that this approach can
work. Treatment of infected individuals with an immunomodulator that can modify
the course of the infection and progression to AIDS has the potential to offer
hope to many chronically infected individuals in South Africa not yet eligible
for antiretroviral therapy” said Dr. Eftyhia Vardas, the Principal Investigator
of FIT Biotech`s clinical study. Dr. Vardas was recently nominated as Honorary
Professor in the Department of Clinical Virology, University of Stellenbosch,
South Africa.

“Once it has been tested in additional clinical trials, FIT-06 has the potential
to offer several big advantages,” said Kalevi Reijonen, President & CEO of FIT
Biotech. “Immediate benefits to patients include the possibility that the start
of antiretroviral therapy could be delayed and that patients might be able to
take longer drug holidays. Also, by reducing their lifetime drug burden, FIT-06
therapy might lessen the side effects associated with long-term use ofo
antiretroviral therapy. Finally, FIT-06 could contribute to a slowing in the
evolution of drug-resistant strains of HIV.”

The results will be presented today at the XVIII International AIDS 2010
Conference in Vienna. There will be both a poster presentation as well as a
press conference featuring Drs. Pantaleo and Vardas as well as a representative
of FIT Biotech.

FIT-06 is a DNA-based vaccine developed by FIT Biotech and based on FIT
Biotech`s novel, proprietary GTU technology. As a therapeutic vaccine, it is
distinct from prophylactic (preventative) vaccines currently in development.
FIT-06 is used to treat patients who are already infected. FIT-06 in particular
and GTU technology in general represent an exciting new platform that, compared
to many other HIV vaccine technologies, offers advantages such as more sustained
expression of the inserted sequences, low dose requirements and an excellent
safety profile. In this trial, FIT-06 was tested as a standalone treatment but
in principle it could also be deployed in conjunction with ART.

The placebo-controlled Phase II study included sixty previously untreated
volunteers recruited at the University of Witwatersrand Clinic in Soweto,
Johannesburg, South Africa. At enrollment, patients had a plasma viral load of
greater than 38,000 copies per ml and a CD4 cell count of more than 500 cells
per µl. Patients were dosed either intramuscularly (IM) or intradermally (ID).
The results, which were more impressive in the intramuscular group, were
analyzed at the end of the study, which concluded after 108 weeks. Viral loads
were reduced by 0.47 log with a p-value of 0.001 in the intramuscular group. CD4
cell counts increased by 72 cells per µl with a p-value of 0.013.

There are more than 33 million HIV-positive people in the world today, with 5.7
million in South Africa alone, including 3.2 million women. The country`s
anti-retroviral programme has been in place since 2004 and more than 500,000
people have been treated.

FORUM

In addition to presenting these data in a poster session at the XVIII
International AIDS Conference on July 19, FIT Biotech will be presenting its
approach at a Community Forum entitled “Research Advances from Therapeutic HIV
Vaccines and Other Immune-Based Therapies.” The Forum takes place on Thursday,
July 22 in room Schubert 5, first floor, from 9:45 to 11am.

PARTNERS

Based on these excellent results, further studies with FIT-06 are planned both
in a standalone setting and in conjunction with ART. These trials will be
conducted in conjunction with FIT Biotech`s public partners:

* ANRS – Agence Nationale de Recherches sur le Sida et les hépatites virales
(www.anrs.fr);
* HVTN – HIV Vaccine Trial Network (www.hvtn.org)
* Imperial College London (www.imperial.ac.uk), Medical Research Council
* EU-FP7, EU Framework 7 Funded Large Integrated Project CUT`HIVAC
(http://cordis.europa.eu/fp7)

ABOUT FIT BIOTECH

FIT Biotech (www.fitbiotech.com) is an innovative medical biotechnology company
based in Tampere, Finland and Tartu, Estonia. FIT Biotech is developing and
commercialising its proprietary Gene Transport Unit (GTU) technology including
FIT-06 for HIV/AIDS. Other GTU product applications include novel DNA
vaccination and immuno- and gene therapies for other infectious diseases
including neglected and emerging diseases with high unmet medical need.

FIT Biotech Ltd.
Dr. Kalevi Reijonen, + 358 408 435 695
CEO & President
kalevi.reijonen@fitbiotech.com
Web: www.fitbiotech.com

Copyright Business Wire 2010

CureVac GmbH: CureVac starts Phase IIa with mRNA immunotherapeutic in Non-Small Cell Lung Cancer

CureVac GmbH / CureVac starts Phase IIa with mRNA immunotherapeutic in Non-Small Cell
Lung Cancer processed and transmitted by Hugin AS. The issuer is solely responsible for
the content of this announcement.

*

The company begins Phase IIa trial with CV9201 in Non-Small Cell Lung Cancer

*

CV9201 is CureVac’s second RNActive® therapeutic vaccine to enter Phase IIa clinical
development

*

First results expected by end of 2011

Tuebingen (Germany), June 16, 2010. CureVac GmbH, the mRNA company, today announced that
the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has
approved the start of a Phase IIa trial for CV9201 to treat Non-Small Cell Lung Cancer
(NSCLC). Results so far from the Phase I study suggest CV9201, an RNActive®-derived mRNA
immunotherapeutic, to be safe and well tolerated when tested in patients with advanced
NSCLC who were pre-treated with standard therapies. The clinical trial with CV9201 will
now enter its Phase IIa part which will further evaluate the safety and tolerability as
well as the pharmacodynamics of the vaccine.

The multicentre trial will be conducted in multiple sites in Switzerland and Germany.
CV9201 will be delivered directly into the skin by intradermal injection. CureVac
expects preliminary results to be available by the end of 2011.

CV9201 is CureVac’s second RNActive® derived candidate for the active immunotherapy of
cancer. The therapeutic vaccine comprises modified mRNA components coding for five
different antigens frequently expressed by NSCLC cells.

“With Phase I results for both immunotherapeutics: CV9201 and CV9103 in NSCLC and
prostate cancer, respectively, we are clearly meeting in the clinical development of
this novel class of therapeutic vaccines,” said Ingmar Hoerr, Managing Director of
CureVac. “Now, we will focus on continuing the clinical trials of these interesting
compounds.”

###

About CureVac

CureVac GmbH is a biopharmaceutical company specializing in the prophylactic and
therapeutic application of messenger RNA (mRNA). CureVac’s lead programme is dedicated
to the development of active tumor immunotherapies, based on its RNActive technology.
Furthermore CureVac develops prophylactic vaccines to protect from viral infections as
well as adjuvants.

Currently, there are two candidates in clinical stage: CV9103 to treat prostate cancer,
which in the U.S. and Europe is the most common cancer and the second leading cause of
cancer death in men. Additionally, CV9201, to treat non-small cell lung cancer (NSCLC).
Lung cancer affects more than 1.4 million people worldwide and is the leading cause of
cancer death.

CureVac, a spin-off from the Tübingen University, Germany, was established in December
2000 and is headquartered in Tübingen with clinical development facilities in Frankfurt.
Since its inception, the Company has raised approximately EUR 65 million. The principal
investor of the company is dievini Hopp BioTech holding GmbH&Co. KG, a venture capital
firm owned by the Hopp family.

RNActive, RNAdjuvant, PUREmessenger are registered trademarks of CureVac GmbH.

About CureVac’s mRNA-derived Technologies

Messenger ribonucleic acid (mRNA) is a genetic template for protein synthesis. It
delivers the information encoded by genes from DNA to ribosomes where the information is
translated into individual proteins. Natural RNA is an unstable biomolecule that is
rapidly digested in the human body.

CureVac has proved it is possible to modify mRNA making it suitable for therapeutic
purposes and maintaining its physiological properties. CureVac’s RNActive®-derived
customized mRNA molecules are used to encode e.g. different tumour-associated antigens
which are expressed by cells residing in the upper layers of the skin. Hence, the immune
system will recognize these antigens on presentation to dendritic cells and react by
forming both antigen-specific T-cells and humoral antibodies.

Building on its unique expertise from many years of RNA research and molecular design
the Company has established proprietary technologies. Furthermore, CureVac has built up
a worldwide unique processing plant for manufacturing mRNA according cGMP (current Good
Manufacturing Practice). The combination of these technologies enables the Company to
design and manufacture mRNA for a broad range of applications.

Contact

CureVac GmbH

Marijke Barner, PhD

Paul-Ehrlich-Str. 15

72076 Tübingen

Germany

T +49 (0) 70 71.92 0 53-0

F +49 (0) 70 71.92 0 53-11

Marijke.Barner@curevac.com mailto:Marijke.Barner@curevac.com

www.curevac.com http://www.curevac.com/

MC Services AG

Hilda Juhasz

T +49 (0) 89.210 228 20

Hilda.Juhasz@mc-services.eu mailto:Hilda.Juhasz@mc-services.eu

HUG#1424162

Press release (PDF) http://hugin.info/141325/R/1424162/372857.pdf

— End of Message —

CureVac GmbH
Paul-Ehrlich-Str. 15 Tübingen Germany

Protein that makes local bladder cancer invasive found

Washington, May 15 (ANI): Researchers at the Kimmel Cancer Center at Jefferson have identified a protein, which, according to them, is involved in pushing tumours to become invasive – and deadly.

It is known that bladder cancer often becomes aggressive and spreads in patients despite treatment.

“We have found that IGF-IR is a critical regulator of motility and invasion of bladder cancer cells, and this could offer us a novel molecular target to treat patients with this cancer in order to prevent metastasis,” said the lead investigator, Dr. Andrea Morrione, a research associate professor of Urology at Jefferson Medical College.

The researchers claim that the finding is promising because there are about a dozen agents targeted against the protein, the insulin-like growth factor receptor I (IGF-IR), that are now undergoing clinical testing to treat a variety of patient tumours.

“Testing presence of the protein could also serve as a novel tumour biomarker for diagnosis, and possibly prognosis of bladder tumours,” he added.

Although bladder cancer is common, the molecular mechanisms that push the cancer to become invasive and to spread are still poorly understood, say the researchers.

Although most bladder cancers are caught early and treated, they often come back and become aggressive, despite subsequent therapy with surgery, chemotherapy, or immunotherapy.

In the study, the researchers looked at the role of the protein receptor for the growth factor IGF-I, an important modulator of cell proliferation in bladder cancer cells.

They found that although activation of IGF-IR did not affect growth of bladder cancer cells, it did promote the migration and invasion of these cells.

The researchers showed that IGF-IR activated other molecules in cancer-promoting pathways (Akt and MAPK) that allow cancer cells to break its bond with other cells in a tumor in order to travel to others sites in the body.

“These data seem to indicate that this protein receptor may play a more prominent role in later stages of bladder cancer, not in the initiation of the cancer,” said Morrione.

Additional work is needed to validate the role of IGF-IR in pushing bladder cancer into an invasive form, but if the results continue to be promising, it might be possible to test anti IGF-IR therapies in bladder cancer and to see how effective a test for these proteins in bladder tumor biopsies might predict cancer spread, the researchers say.

The study has been published in the June issue of American Journal of Pathology. (ANI)

New drug type developed to kill lymphoma cells

Washington, May 11 (ANI): Scientists have developed a new type of drug designed to kill non-Hodgkin lymphoma tumour cells.

The breakthrough could lead to potential non-toxic therapies for cancer patients.

The researchers, including Dr. Ari Melnick, of Weill Cornell Medical College, Dr. Alexander MacKerell, of the University of Maryland and Dr. Gilbert Prive, of the University of Toronto, have identified a drug that targets an oncogene known as BCL6.

BCL6 functions as a master regulatory protein.

“It”s a protein that controls the production of thousands of other genes. Because of that, it has a very profound impact on cells and is required for lymphoma cells to survive and multiply,” said Melnick.

BCL6 causes the majority of diffuse large B cell lymphomas, the most common form of non-Hodgkin lymphoma.

Currently, about 60 percent of diffuse large B cell lymphomas can be cured with chemo-immunotherapy, said Melnick.

“The hope is that we can improve that to a higher percent, and in the long term reduce the need for chemotherapy,” he added.

Traditional cancer drugs target enzymes, which have small pockets on their surfaces that can be blocked with molecules.

Until now, pharmaceutical companies have been reluctant to create drugs that target a protein like BCL6 because they function through a different mechanism involving interactions with cofactor proteins involving extensive protein surfaces.

“And because the real estate covered by these interactions is so large, the drug companies have viewed these as being not druggable targets,” said Melnick.

The researchers could identify a “hot spot” on BLC6 that they predicted would play a critical role in protein interactions.

They showed that their BCL6 inhibitor drug was specific to BCL6, and did not block other master regulatory proteins.

The drug had powerful lymphoma killing activity and yet was non-toxic to normal tissues.

“This is the first time a drug of this nature has been designed and it shows that it”s not actually impossible to target factors like BCL6,” he said.

Emerging data from other investigators suggests that BCL6 is important in many other tumor types, including forms of leukemia.

The study has been published in a recent issue of Cancer Cell. (ANI)

Immunotherapy against pollen allergy can help prevent asthma

Hamburg, Germany – Spring has arrived in the northern hemisphere – and with it, a time of suffering for those who are susceptible to hay fever. About 10 million people in Germany are allergic to pollen, said the Association of German Allergists in Hamburg, northern Germany,.

Although most sufferers try to deal with the symptoms themselves, that can have potentially dangerous consequences.

“At least one third of all patients, who have an allergy that they don’t treat properly, will suffer from allergic asthma in the short or long term,” said Thomas Fuchs, a representative of the association.

Starting a course of immunotherapy as early as possible is the best way of avoiding complications.

“In the best case scenario, you begin immunotherapy at a maximum of five years after the symptoms of a pollen allergy appear,” says Professor Karl-Christian Bergmann from the Allergy Centre at Berlin’s Charite University Clinic.

The earlier immunotherapy begins, the fewer allergies are present and the less developed they are, thereby improving the chances of a successful therapy.

Immunotherapy begins when the body is exposed to a very low concentration of the allergen. The dosage is then slowly increased over a long period of time.

As the concentration is increased, the body’s immune system becomes less sensitive to the allergen.

“The effectiveness of this treatment has been proven in many studies and is very successful when it comes to hay fever sufferers,” says Anja Schwalfenberg, a biologist and consultant at the German Allergy and Asthma Association in Moenchengladbach.

But Schwalfenberg advises against following a specific course of immunotherapy in cases of severe asthma or asthma that has not been treated properly.

“The gold standard among forms of therapy is what is known as subcutaneous therapy, where the allergen is injected under the skin,” explains Heidrun Holstein, a doctor at the Consumers Association office in Karlsruhe.

But this type of therapy takes a long time to complete. “In the beginning, the patient receives an injection between two and three times a week in a clinic. In some cases, a long-acting agent which releases the allergen over a period of time may be injected once a week.”

This therapy is begun before the hay fever season starts. Side effects include drowsiness or in extreme cases allergic shock, which is why patients must remain under observation in the clinic for 30 minutes after being treated.

Researchers have developed alternative treatments that no longer require the patient to receive an injection.

Sublingual therapy consists of drops of vaccine that are placed in the patient’s mouth. Grass allergies can be treated with tablets.

The most noticeable side effect of injected vaccines has been observed in patients such as asthma sufferers who have oversensitive bronchi.

“Those patients should receive a course of drops under medical observation,” advises Bergmann.

All other patients should consult their doctor every three months to receive a new prescription. (dpa)